SOHO 2020 Program

The Society of Hematologic Oncology's Eighth Annual Meeting will be held on September 9-12, 2020 as a virtual event. The focus of the 3.5-day program is state-of-the-art approaches in the field of hematologic malignancies.

The virtual meeting offers participants:

live-stream multi-track session broadcast with live lectures, debates, plenary sessions and more
ability to engage with other virtual participants and presenters
'live', virtual poster session and ongoing access to the poster hall for viewing, discussions and collaborations
access to the virtual exhibit hall for discussions, information and FREE give-aways
on-demand recordings for 4-months following the annual meeting
digital copy of speakers' slides, final program and abstract proceedings published in the official CLML journal supplement
CME credits for physicians and CNE credits for nurses

You may view the SOHO 2020 session line-up in the Program-at-a-Glance, the detailed program by day or download a copy of the program in PDF format. Note that all times in the program are listed in Central Daylight Time (CDT) which is 5 hours behind Coordinated Universal Time (UTC -5).

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
MEET-THE-PROFESSOR SESSION I
6:45 AM	MTP Session I: AML
	Session Chair: Vitae Vyas
	IDH Inhibition	Stéphane De Botton, MD	Institut de Cancérologie Gustave Roussy, Paris, France
	FLT3 Inhibition	Catherine Smith, MD	University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
	Approaches to Understand Mechanisms of Resistance and Response To AML Therapies Using Single Cell Approaches	Vitae Paresh Vyas, MRCPath, FRCP, FRCPath	Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
6:45 AM	MTP Session II: ALL
	Session Chair: Ching-Hon Pui
	How the COG is Approaching the High-Risk Patient with ALL – Incorporation of CAR-T into Frontline Therapy	Jennifer McNeer, MD, MS	The University of Chicago Medicine, Chicago, Illinois, USA
	Management of Asparaginase Toxicity in AYAs with ALL	Kjeld Schmiegelow, MD	Copenhagen University Hospital, Copenhagen, Denmark
	How to Use a MRD Result in AYAs Receiving Pediatric Regimens?	Aaron Logan, MD, PhD	UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA
6:45 AM	MTP Session III: NHL
	Session Chair: Nathan Fowler
	What is the Optimal Frontline Regimen in FL	Nathan H. Fowler, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	CNS Lymphoma	Christopher R Flowers, MD, MS	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Role of Transplant in Lymphoma	Sonali M. Smith, MD, FASCO	The University of Chicago, Chicago, Illinois, USA
6:45 AM	MTP Session IV: NHL
	Session Chair: Laurie Sehn
	Double Hit Lymphoma	Laurie Sehn, MD, MPH	BC Cancer, Vancouver, Canada
	CAR T-Cell Therapy for Lymphoma	Sattva Neelapu, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Hodgkin Lymphoma	Pier Luigi Zinzani, MD	University of Bologna, Bologna, Italy
6:45 AM	MTP Session V: CML
	Session Chair: Jerry Radich
	Selecting the Right TKI	Jorge Cortés, MD	Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
	CML Management in Resource Limited Countries	Jerald P. Radich, MD	University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
	Is NGS Ready for Clinical Practice: Advantages and Limitations	Simona Soverini, MD	University of Bologna, Bologna, Italy
6:45 AM	MTP Session VI: MPN
	Session Chair: Uday Popat
	CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?
	A Young Woman with Thrombocytosis	Prithviraj Bose, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	A Young Man with Polycythemia Vera and Fatigue	Gabriela Hobbs, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
	A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis	Uday Popat, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM	MTP Session VII: MDS
	Session Chair: Koichi Takahashi
	The Spectrum of Clonal Hematopoiesis from CHIP to AML	Koichi Takahashi, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Challenges in Diagnosis and Risk Stratification of MDS	Aziz Nazha, MD	Cleveland Clinic, Cleveland, Ohio, USA
	Pitfalls in Assessing Response to Treatment in MDS	Uwe Platzbecker, MD	Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
6:45 AM	MTP Session VIII: MM
	Session Chair: Thomas Martin
	Latest Treatment Approaches in AL Amyloidosis	Suzanne Lentzsch, MD, PhD	Columbia University and at New York Presbyterian Hospital, New York, USA
	Emerging Therapies	Thomas G. Martin, MD	University of California San Francisco, San Francisco, California, USA
6:45 AM	MTP Session IX: CLL
	Session Chair: Emili Montserrat
	BTK and Monoclonal Antibodies	Carol Moreno, MD, PhD	Hospital de la Santa Creui Sant Pau, Autonomous University of Barcelona, Barcelona, Spain
	BTK and CIT	Philip A. Thompson, MB, BS	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	BTK and BCL2	Nitin Jain, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:45 AM	MTP Session X: CT
	Session Chair: Susan Prockop
	EBV CTLs for PTLD– Ready for Prime Time	Susan Prockop, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
	CD19 CAR T Cells for Adults	David L. Porter, MD	University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
	Vaccines and Immunotherapy	David E. Avigan, MD	Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA
7:45 AM	EXHIBIT HALL EXPERIENCE
MEET-THE-PROFESSOR SESSION II
8:00 AM	MTP Session XI: AML
	Session Chair: Courtney DiNardo
	Changing the Treatment Paradigm in AML	Daniel Pollyea, MD, MS	University of Colorado, Denver, Colorado, USA
	Targeting the Microenvironment	Geoffrey L. Uy, MD	Washington University School of Medicine, St. Louis, Missouri, USA
	Familial AML	Courtney D. DiNardo, MD, MSCE	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session XII: ALL
	Session Chair: Elias Jabbour
	How I Approach the Treatment of T-ALL in Adults in 2020	Nitin Jain, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	How I Treat the Older Adult with B-ALL	Elias Jabbour, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	How I Approach the Patient Who Has MRD Or Relapse After Transplant	Lori Muffly, MD	Stanford University Medical Center, Palo Alto, California, USA
8:00 AM	MTP Session XIII: NHL
	Session Chair: Pier Luigi Zinzani
	Primary Mediastinal Large Cell Lymphoma	Pier Luigi Zinzani, MD	University of Bologna, Bologna, Italy
	Role of Radiation Therapy in HL	Joachim Yahalom, MD, FACR	Memorial Sloan-Kettering Cancer Center, New York, New York, USA
	Chemo Free Regimens in Lymphoma	Loretta Nastoupil, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session XIV:NHL
	Session Chair: Ariela Noy
	Novel Treatments for Aggressive Lymphoma	Christopher R Flowers, MD, MS	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Treatment of Early Stage DLBCL	Daniel O. Persky, MD	University of Arizona Cancer Center, Tucson, Arizona, USA
	Burkitt Lymphoma	Ariela Noy, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
8:00 AM	MTP Session XV: CML
	Session Chair: Jerry Radich
	Selecting the Right TKI	Jorge Cortés, MD	Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
	CML Management in Resource Limited Countries	Jerald P. Radich, MD	University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
	Is NGS Ready for Clinical Practice: Advantages and Limitations	Simona Soverini, MD	University of Bologna, Bologna, Italy
8:00 AM	MTP Session XVI: MPN
	Session Chair: Uday Popat
	CASE STUDIES IN MPN: WHEN IS TREATMENT NECESSARY?
	A Young Woman with Thrombocytosis	Prithviraj Bose, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	A Young Man with Polycythemia Vera and Fatigue	Gabriela Hobbs, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
	A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis	Uday Popat, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:00 AM	MTP Session XVII: MDS
	Session Chair: Rami Komrokji
	How Do I Treat: Lower Risk MDS	Valeria Santini, MD	University of Florence, Florence, Italy
	How Do I Treat: Higher Risk MDS	Rami Komrokji, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
	How Do I Treat: MDS/MPN	Eric Padron, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
8:00 AM	MTP Session XVIII: MM
	Session Chair: Sheeba Thomas
	Waldenstroms Macroglobunemia	Sheeba K. Thomas, MD	The University of Texas MD Anderson Cancer Center, Houston, TX, USA
	Bone Diseases and Supportive Care	Jens Hillengass, MD	Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
8:00 AM	MTP Session XIX: CLL
	Session Chair: Phil Thompson
	Managing BTK Inhibitor Toxicities	Alessandra Ferrajoli, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	Managing BCL2 Toxicities	John Seymour, MBBS, FRACP, PhD	Peter MacCallum Cancer Centre & the Royal Melbourne Hospital, Melbourne, Australia
	Managing Cellular Therapy Toxicities	Jae Park, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
8:00 AM	MTP Session XX: CT
	Session Chair: Sergio Giralt
	Point of Care CAR T Cells	Marcos de Lima, MD	UH Cleveland Medical Center, Cleveland, Ohio, USA
	CAR vs Transplant for NHL	Richard Maziarz, MD	Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA
	Role of CAR T Cells in Relapsed Myeloma	Andrzej Jakubowiak, MD, PhD	University of Chicago Medical Center, Chicago, Illinois, USA
9:00 AM	EXHIBIT HALL EXPERIENCE
TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
SESSION I: ACUTE LYMPHOBLASTIC LEUKEMIA
Session Chairs: Dieter Hoelzer and Wendy Stock
9:15 AM	Welcome and Opening Remarks	Sagar Lonial, MD	President, Society of Hematologic Oncology
9:25 AM	In Relapsed B-ALL, How Should We Best Sequence the New Targeted Agents?	Emily Curran, MD	The University of Cincinnati, Cincinnati, Ohio, USA
9:40 AM	Q & A
9:43 AM	Mini-Hyper – CVD Combinations for Older Adults: Results of Recent Trials and A Glimpse Into the Future	Marlise R. Luskin, MD, MSCE	Dana Farber Cancer Institute, Boston, Massachusetts, USA
9:58 AM	Q & A
10:01 AM	Who Should Receive An Allogeneic Transplant in First Complete Remission?	Josep-Maria Ribera, MD, PhD	Catalan Institute of Oncology, Barcelona, Spain
10:16 AM	Q & A
10:19 AM	What’s the Latest Innovation in CAR-T Therapy? Fast-Off, Dual Targeting and Other New Tricks	Martin Pule, MB BCh, MRCP	Cancer Institute, University College London, London, United Kingdom
10:34 AM	Q & A
10:37 AM	Genomics of Drug Response in ALL: Predicting Response and Concerns for Triggering Relapse	Jun J. Yang, PhD	St. Jude Children's Research Hospital, Memphis, Tennessee, USA
10:52 AM	Q & A
10:55 AM	DEBATE:Is Less more? Intensive vs Non-Intensive Approach To Adults with Ph+ ALL \| Intensive Approach	Nicholas Short, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
11:10 AM	DEBATE:Is Less More? Intensive vs Non-Intensive Approach To Adults with Ph+ ALL \| Non-Intensive Approach	Sabina Chiaretti, MD, PhD	Sapienza University, Rome, Italy
11:25 AM	Q & A
11:31 AM	Oral Abstract: ALL-312 Sixteen Years' Experience in Treating Adolescents and Young Adult (AYA) with Philadelphia-Negative Acute Lymphoblastic Leukemia (Ph- ALL) with a Modified Pediatric ALL Protocol	Saleem Eldadah, MD	Princess Noorah Oncology Center, Ministry of the National Guard - Health Affairs, Jeddah, Saudi Arabia
INDUSTRY EXPERT SESSION IA
11:41 AM	An Acute Myeloid Leukemia Treatment Option for Patients	Hetty Carraway, MD, MBA	Cleveland Clinic, Cleveland, Ohio, USA
	This activity is supported by Bristol-Myers Squibb
INDUSTRY EXPERT SESSION IB
11:41 AM	A CAR T-cell Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma TECARTUS™ (brexucabtageneautoleucel) Prescribing Information	David Rizzieri, MD	Duke University School of Medicine, Durham, North Carolina, USA
	This activity is supported by Kite Pharma
12:41 PM	EXHIBIT HALL EXPERIENCE
PLENARY SESSION I
Session Chair: Sagar Lonial
1:11 PM	Keynote Speaker: Immunotherapy for T-Cell ALL and T-NHL	John DiPersio, MD, PhD	Washington University, St. Louis, Missouri, USA
	Recipient of the SOHO 2020 Distinguished Lecturer Award
SESSION II: MYELODYSPLASTIC SYNDROMES
Session Chairs: Guillermo Garcia-Manero and Valeria Santini
1:31 PM	New Approaches for Anemia in MDS	Uwe Platzbecker, MD	Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany
1:46 PM	Q & A
1:49 PM	Development of Oral HMAs for MDS	Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:04 PM	Q & A
2:07 PM	Targeting BCL-2 in MDS	Amer Zeidan, MBBS	Yale Cancer Center, New Haven, Connecticut, USA
2:22 PM	Q & A
2:25 PM	Targeting p53 in MDS	David Sallman, MD	H. Lee Moffitt Cancer Center, Tampa, Florida, USA
2:40 PM	Q & A
2:43 PM	IDH Inhibitors in MDS	Courtney D. DiNardo, MD, MSCE	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:58 PM	Q & A
3:01 PM	Oral Abstract: MDS-254 SF3B1 Splicing Mutation in the Context of Therapy-Related MDS	Virginia Volpe, MD	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
3:11 PM	EXHIBIT HALL EXPERIENCE
SESSION III: ACUTE MYELOID LEUKEMIA
Session Chairs: Richard Stone and Farhad Ravandi
3:41 PM	State of the Art in AML	Laura C. Michaelis, MD	Medical College of Wisconsin, Milwaukee, Wisconsin, USA
3:56 PM	Q & A
3:59 PM	Germline Mutations in AML	Coleman Lindsley, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
4:14 PM	Q & A
4:17 PM	Harnessing Apoptosis in AML	Marina Konopleva, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4:32 PM	Q & A
4:35 PM	The Problem of Mutant P53 AML	David Sallman, MD	H. Lee Moffitt Cancer Center, Tampa, Florida, USA
4:50 PM	Q & A
4:53 PM	Targeting CD123 in AML	Andrew A. Lane, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
5:08 PM	Q & A
5:11 PM	DEBATE: Fit Older Adults Between 60-75 in First Remission On Either Extreme of the Prognostic Spectrum Should Undergo Allo SCT	Edwin Pascal Alyea, MD	Duke University School of Medicine, Durham, North Carolina, USA
5:26 PM	Q & A
5:26 PM	DEBATE: Fit Older Adults Between 60-75 in First Remission On Either Extreme of the Prognostic Spectrum Should Not Undergo Allo SCT	Uma Borate, MD, MS	Oregon Health & Science University, Portland, Oregon, USA
5:41 PM	Q & A
5:47 PM	Novel Antibodies in AML	Marion Subklewe, MD	Ludwig-Maximilians-University of Munich, Munich, Germany
6:02 PM	Q & A
6:05 PM	Oral Abstract: AML-063 A Randomized, Double-Blind, Placebo-Controlled Study of Venetoclax with Azacitidine Versus Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia Ineligible for Intensive Therapy-Viale-A	Courtney D. DiNardo, MD, MSCE	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
6:15 PM	ADJOURN
POSTER SESSION & WELCOME RECEPTION
6:15 PM	POSTER SESSION
6:15 PM	WELCOME RECEPTION AND AWARDS
INDEPENDENT SATELLITE SYMPOSIUM I
8:15 PM	Relapsed/Refractory Multiple Myeloma: What’s Next for Patients?
	Jesus Berdeja, MD, Tennessee Oncology and Joshua Richter, MD, Mount Sinai
	This CME activity is jointly provided by Purdue University College of Pharmacy, RedMedEd, and the Multiple Myeloma Research Foundation. This activity is supported by educational grants from Amgen and Bristol-Myers Squibb, and Oncopeptides Please visit https://tinyurl.com/RMESOHO20 for more information on this program.


TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM II
6:15 AM	The Evolving Therapeutic Landscape in Relapsed Refractory Multiple Myeloma Sagar Lonial, MD, FACP \| Emory University, Atlanta, USA – Chair Adam Cohen, MD \| University of Pennsylvania, Philadelphia, USA \| Shaji Kumar, MD \| Mayo Clinic, Rochester, Minnesota, USA This Activity is supported by GlaxoSmithKline
BREAKFAST WITH THE EXPERT I
6:45 AM	CAR T for Myeloid Leukemias– Current Status	Elizabeth L. Budde, MD, PhD	City of Hope National Medical Center, Duarte, California, USA
7:45 AM	EXHIBIT HALL EXPERIENCE
SESSION IV: MYELOPROLIFERATIVE NEOPLASMS
Session Chairs: Srdan Verstovsek and Laura Michaelis
8:00 AM	Genomics in Myelofibrosis: Practical Guidelines for Its Use in Clinical Practice	Raajit K. Rampal, MD, PhD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
8:15 AM	Q & A
8:18 AM	New Therapies in Development for Myelofibrosis	Srdan Verstovsek, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:33 AM	Q & A
8:36 AM	Improved Outcomes with Transplant for MPN	Upday Popat, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
8:51 AM	Q & A
8:54 AM	CASE PRESENTATION: Thrombosis in PV: How To Predict and How To Reduce the Risk	Gabriela Hobbs, MD	Massachusetts General Hospital, Boston, Massachusetts, USA
9:09 AM	Q & A
9:12 AM	CASE PRESENTATION: Post PV and Post ET MF: What A Doctor Needs To Know	Laura C. Michaelis, MD	Medical College of Wisconsin, Milwaukee, Wisconsin, USA
9:27 AM	Q & A
9:30 AM	Oral Abstract: MPN-188 Myeloablative Regimen in Myelofibrosis (MF): Long-Term Outcomes and Analysis of Prognostic Factors	Jacinth Joseph, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:40 AM	EXHIBIT HALL EXPERIENCE
SESSION V: MULTIPLE MYELOMA
Session Chairs: Sagar Lonial and Thomas Martin
10:10 AM	Frontline Therapy for Frail Older Patients	Brea C. Lipe, MD	The University of Rochester, Rochester, New York, USA
10:25 AM	Q & A
10:28 AM	DEBATE: Frontline Therapy for Fit MM Patients Should Include an Antibody	Peter M. Voorhees, MD	Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA
10:43 AM	DEBATE: Frontline Therapy for Fit MM Patients Should NOT Include an Antibody	Thomas G. Martin, MD	University of California San Francisco, San Francisco, California, USA
10:58 AM	Q & A
11:04 AM	DEBATE: Smoldering MM Should Be Treated Early	Maria-Victoria Mateos, MD, PhD	University Hospital of Salamanca, Spain
11:19 AM	DEBATE: Smoldering MM Should NOT Be Treated Early	Angela Dispenzieri, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
11:34 AM	Q & A
11:40 AM	Role of HDT in Current Treatment for MM	Ajay K. Nooka, MD, MPH, FACP	Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
11:55 AM	Q & A
11:58 AM	Management of Early Relapse	Robert Z. Orlowski, MD, PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:13 PM	Q & A
12:16 PM	Oral Abstract: MM-350 Subgroup Analysis of GRIFFIN in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)	Ajay K. Nooka, MD, MPH, FACP	Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
INDUSTRY EXPERT SESSION IIA
12:26 PM	IMMUNO-ONCOLOGY AND MDS: Current Knowledge and Future Perspectives	Naval Daver, MD Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	This activity is supported by Novartis
INDUSTRY EXPERT SESSION IIB
12:26 PM	Intervening with Jakafi (ruxolitinib) to Achieve Durable Count Control: Real World Patient Case Discussion Focus on Adults With Polycythemia Vera Who Have an Inadequate Response to Hydroxyurea	David Rizzieri, MD	Duke University School of Medicine, Durham, North Carolina, USA
	This activity is supported by Incyte
PLENARY SESSION II
Session Chair: Sagar Lonial
1:56 PM	BCMA Directed Therapy for MM	Nikhil C. Munshi, MD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
SESSION VI: CHRONIC LYMPHOCYTIC LEUKEMIA
Session Chairs: Jennifer Brown and Florence Cymbalista
2:16 PM	Next Generation of BCR Inhibitors	Paolo Ghia, MD, PhD	Università Vita-Salute San Raffaele, Milano, Italy
2:31 PM	Q & A
2:34 PM	Measuring Residual Disease, Clinical Implications	William Wierda, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
2:49 PM	Q & A
2:52 PM	What Is Fitness in the Era of Targeted Agents	Alessandra Tedeschi, MD	Niguarda Cancer Center, ASST Grande Ospedale Metropolitan Niguarda, Milan, Italy
3:07 PM	Q & A
3:10 PM	Debate: BTK Inhibitor Is the Best Frontline Option for CLL	John C. Byrd, MD	The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
3:25 PM	Debate:BCL2 Inhibitor Is the Best Frontline Option for CLL	Michael Hallek, MD	University of Cologne, Cologne, Germany
3:40 PM	Q & A
3:46 PM	Cellular Therapies in CLL	Elizabeth J. Shpall, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
4:01 PM	Q & A
4:04 PM	Oral Abstract: CLL-091 ASCEND Final Results in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)	Paolo Ghia, MD, PhD	Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
4:14 PM	EXHIBIT HALL EXPERIENCE
4:44 PM	ADJOURN
INDUSTRY EXPERT SESSION III
4:44 PM	A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients Resistant/Intolerant to Prior TKI Therapy	Jorge Cortés, MD	Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
	This activity is supported by Pfizer
INDUSTRY EXPERT SESSION IV
5:44PM	A Case-Based Discussion on Improving Outcomes in Patients with Newly-Diagnosed Secondary AML	Usama Gergis, MD, MBA	Weill Cornell Medical College, New York, New York, USA
	This activity is supported by Jazz Pharmaceuticals Inc.
INDEPENDENT SATELLITE SYMPOSIUM III
6:44 PM	Myeloproliferative Neoplasms: Integrating New Therapies Into Challenging Case Scenarios Prithviraj Bose, MD - Chair; Ruben Mesa, MD; Raajit K. Rampal, MD, PhD This CME Activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol-Myers Squibb and Incyte. For more information and to register for this ISS, go to TBD.

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM IV
6:30 AM	Achieving Innovation in CLL Care with BTK Inhibitors: Selection, Safety, and Sequencing Across the Disease Continuum Speakers: William G. Wierda, MD, PhD \| Philip A. Thompson, MB, MS \| The University of Texas MD Anderson Cancer Center This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from AstraZeneca. For more information and to register for the live ISS, go to PeerView.com/CLL20Live
BREAKFAST WITH THE EXPERT II
6:45 AM	How to Move Beyond RCHOP	Sandeep S. Dave, MD, MS	Duke University School of Medicine, Durham, North Carolina, USA
7:45 AM	EXHIBIT HALL EXPERIENCE
SESSION VII: HODGKIN LYMPHOMA
Session Chairs: David Straus
8:00 AM	Newly Diagnosed HL	David J. Straus, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
8:15 AM	Q & A
8:18 AM	Relapsed HL	Alex F. Herrera, MD	City of Hope, Duarte, California, USA
8:33 AM	Q & A
8:36 AM	Oral Abstract: HL-323 Outcomes of First-Line Treatment in Patients with Advanced Clinical Stage Classic Hodgkin Lymphoma and Human Immunodeficiency Virus Infection	Juan José Del Moral, MD	Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
SESSION VIII: T-CELL LYMPHOMA
Session Chairs: Steven Horwitz and Francisco Vega
8:46 AM	Pathology and Pathogenesis of T Cell Lymphoma	Francisco Vega, MD PhD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
9:01 AM	Q & A
9:04 AM	Newly Diagnosed	Kerry Savage, MD	BC Cancer, Vancouver, Canada
9:19 AM	Q & A
9:22 AM	Relapsed T Cell Lymphoma	Steven M. Horwitz, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
9:37 AM	Q & A
9:40 AM	Oral Abstract: TCL-127 Impact of Concomitant Steroids on Mogamulizumab Efficacy in MAVORIC	Larisa Geskin, MD	New York Presbyterian Hospital, New York, NY, USA
9:50 AM	EXHIBIT HALL EXPERIENCE
SESSION IX: INDOLENT B-CELL LYMPHOMA
Session Chairs: Mathias Rummel and Nathan Fowler
10:20 AM	Management of Newly Diagnosed FL	Mathias J. Rummel, MD, PhD	Justus-Liebig University-Hospital, Giessen, Germany
10:35 AM	Q & A
10:38 AM	Relapsed FL	Nathan H. Fowler, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:53 AM	Q & A
10:56 AM	Marginal Zone Lymphoma	Emanuele Zucca, MD	Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
11:11 AM	Q & A
11:14 AM	Waldenstrom	Morie A. Gertz, MD	Mayo Clinic, Rochester, Minnesota, USA
11:29 AM	Q & A
11:32 AM	Oral Abstract: IBCL-344 Marginal Zone Lymphoma: Epidemiology and Outcomes in a Mexican Center	Rosana Córdova, MD	Instituto Nacional de Cancerología, Mexico City, Mexico
INDUSTRY EXPERT SESSION VA
11:42 AM	Redefining Approaches in Frontline Chronic Lymphocytic Leukemia (CLL) Treatment Imbruvica® + Rituximab vs FCR: Head-to-Head- Data in Frontline CLL/SLL	Nakhle Saba, MD Ruemu Birhiray, MD	Tulane University, New Orleans, Louisiana, USA Hematology Oncology of Indiana, Indianapolis, Indiana, USA
	This activity is supported by Janssen Biotech & Pharmacyclics, LLC
INDUSTRY EXPERT SESSION VB
11:42 AM	Explore Yescarta®: CAR T Therapy, for Patients in Your Practice	John Pagel, MD, PhD	Swedish Cancer Institute, Seattle, Washington, USA
	This activity is supported by Kite Pharma
PLENARY SESSION III
Session Chair: Hagop Kantarjian
1:12 PM	My Take on Prognostication and Management of Essential Thrombocythemia	Ayalew Tefferi, MD	Mayo Clinic Rochester, Rochester, Minnesota, USA
SESSION X: AGGRESSIVE B-CELL LYMPHOMA
Session Chairs: Martin Hutchings and Sonali Smith
1:32 PM	Novel Immunotherapeutic Agents in Aggressive B-NHL	Martin Hutchings, MD, PhD	The Finsen Center, National Hospital Copenhagen University Hospital, Copenhagen, Denmark
1:47 PM	Q & A
1:50 PM	Relapsed DLBCL	Sonali M. Smith, MD, FASCO	The University of Chicago, Chicago, Illinois, USA
2:05 PM	Q & A
2:08 PM	CAR T Cells	Peter Riedell, MD	University of Chicago Medicine, Chicago, Illinois, USA
2:23 PM	Q & A
2:26 PM	Oral Abstract: ABCL-256 Role of Radiotherapy Differs Between Stages for Primary Bone Large B-Cell Lymphoma in the Rituximab Era: A Real-World Study	Shengling Ma, MD	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2:36 PM	EXHIBIT HALL EXPERIENCE
SESSION XI: MANTLE CELL LYMPHOMA
Session Chair: Robert Marcus
3:06 PM	Frontline Treatment of Mantle Cell Lymphoma	Steven LeGouill, MD, PhD	Nantes University Hospital, Nantes, France
3:21 PM	Q & A
3:24 PM	Relapsed MCL	Jonathon B. Cohen MD, MS	Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
3:39 PM	Q & A
3:42 PM	Oral Abstract: MCL-129 First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study	Michael L. Wang, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
SESSION XII: CELLULAR THERAPY
Session Chairs: Renier Brentjens and Sergio Giralt
3:52 PM	Adding Vaccines to the Immunotherapy Cocktail	David E. Avigan, MD	Beth Israel Deaconess Medical Center and Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA
4:07 PM	Q & A
4:10 PM	New CAR Designs	Renier J. Brentjens, MD, PhD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
4:25 PM	Q & A
4:28 PM	Optimizing Lymphodepletion Prior to CAR T Cell Therapy	Elizabeth L. Budde, MD, PhD	City of Hope National Medical Center, Duarte, California, USA
4:43 PM	Q & A
4:46 PM	Oral Abstract: CT-279 Story of Success of Haploidentical Hematopoietic Stem Cell Transplantation in Aplastic Anemia: A Systematic Review and Meta-Analysis of Clinical Outcome	Ghada ELGohary, MD	Ain Shams University, Cairo, Egypt
4:56 PM	ADJOURN
INDUSTRY EXPERT SESSION VI
4:56 PM	XOSPATA® (gilteritinib): A Targeted Therapeutic Approach for Relapsed/Refractory FLT3m+ AML Patients	Naval Daver, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
	This activity is supported by Astellas
INDEPENDENT SATELLITE SYMPOSIUM V
5:56 PM	The Rise of Novel Antibodies in Multiple Myeloma: Exploring the Present and Future of Antibody-based Treatment From CD38 to BCMA
	Sagar Lonial, MD, FACP \| Robert Z. Orlowski, MD, PhD
	This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education. This activity is supported by an independent educational grant from GlaxoSmithKline. For more information and to register for the live ISS, go to PeerView.com/MM20-Live
INDEPENDENT SATELLITE SYMPOSIUM VI
6:56 PM	Treating Multiple Myeloma in 2020 – Best Approaches to Optimizing Patient Outcomes
	Robert Z. Orlowski, MD, PhD - Chair \| María-Victoria Mateos, MD, PhD \| Paul Richardson, MD
	This CME activity is jointly provided by the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend. This activity is supported by an educational grant from GlaxoSmithKline and Oncopeptides. For more information and to register for this ISS, go to www.BioAscend.com/SOHOMM.

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDUSTRY EXPERT SESSION VII
6:45 AM	Discover the Role of Two Immunotherapies in Myeloma Treatment Melhem M. Solh, MD \| Northside Hospital Blood and Marrow Transplant and Leukemia Program This activity is supported by Bristol-Myers Squibb
BREAKFAST WITH THE EXPERT III
6:45 AM	CML Update	Michael Deininger, MD, PhD	Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
7:45 AM	EXHIBIT HALL EXPERIENCE
SESSION XIII: CHRONIC MYELOID LEUKEMIA
Session Chairs: Jorge Cortés and Simona Soverini
8:00 AM	CML: State of the Art Update	Delphine Rea, MD, PhD	Hôpital Saint Louis, Paris, France
8:15 AM	Q & A
8:18 AM	New Therapeutic Options in CML	Jorge Cortés, MD	Georgia Cancer Center at Augusta University, Augusta, Georgia, USA
8:33 AM	Q & A
8:36 AM	Update on CML-Like Disorders	Nick Cross, MA, PhD, FRCPath	University of Southampton, Salisbury, United Kingdom
8:51 AM	Q & A
8:54 AM	Case Studies: the Challenges of TFR	Timothy P. Hughes, MD, FRACP, FRCPA	South Australian Health and Medical Research Institute, Adelaide, Australia
9:09 AM	Q & A
9:12 AM	The Molecular Complexity of CML	Jerald P. Radich, MD	University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
9:30 AM	Oral Abstract: CML-109 Exploratory Biomarker Analysis From ENESTnd: Gene Expression Signature Distinguishes Deep Molecular Response (DMR) From Poor Response in Chronic Myeloid Leukemia (CML)	Jerald P. Radich, MD	University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
9:40 AM	EXHIBIT HALL EXPERIENCE
SESSION XIV: NEXT QUESTIONS
Session Chairs: Sagar Lonial and Selina Luger
10:10 AM	Next Questions: Acute Lymphoblastic Leukemia	Selina M. Luger, MD	University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, USA
10:20 AM	Next Questions: Acute Myeloid Leukemia	Amer Zeidan, MBBS	Yale Cancer Center, New Haven, Connecticut, USA
10:30 AM	Next Questions: Cellular Therapy	Sergio Giralt, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
10:40 AM	Next Questions: Myelodysplastic Syndromes	Guillermo Garcia-Manero, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
10:50 AM	Next Questions: Chronic Myeloid Leukemia	Michael Deininger, MD, PhD	Huntsman Cancer Hospital, The University of Utah, Salt Lake City, Utah, USA
11:00 AM	Next Questions: Aggressive B-Cell Lymphoma	Sandeep S. Dave, MD, MS	Duke University School of Medicine, Durham, North Carolina, USA
11:10 AM	Next Questions: Indolent B-Cell Lymphoma	Robert Marcus, MA, FRCP, FRCPath	Leaders in Oncology Care, London, United Kingdom
11:20 AM	Next Questions: T-Cell Lymphoma	Kerry Savage, MD	BC Cancer, Vancouver, Canada
11:30 AM	Next Questions: Mantle Cell Lymphoma	Jonathon B. Cohen MD, MS	Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
11:40 AM	Next Questions: Hodgkin Lymphoma	David J. Straus, MD	Memorial Sloan Kettering Cancer Center, New York, New York, USA
11:50 AM	Next Questions: Multiple Myeloma	Sagar Lonial, MD, FACP	Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
12:00 PM	Next Questions: Chronic Lymphocytic Leukemia	Jennifer R. Brown, MD, PhD	Dana-Farber Cancer Institute, Boston, Massachusetts, USA
12:10 PM	Next Questions: Myeloproliferative Neoplasms	Dr. Prithviraj Bose, MD	The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
12:20 PM	CLOSING REMARKS
12:35 PM	ADJOURN

TIME	TOPIC/SESSION	SPEAKER	AFFILIATION/ROOM
INDEPENDENT SATELLITE SYMPOSIUM VII
	Managing AML: Staying on Track in a Rapidly Changing Treatment Landscape Naval Daver, MD \| Courtney DiNardo, MD \| Eunice Wang, MD This CME activity is provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol-Myers Squibb, Jazz Pharmaceuticals and Actinium
INDEPENDENT SATELLITE SYMPOSIUM VIII
	Targeting Treatment in Relapsed/Refractory Multiple Myeloma: Experts Discuss Novel Agents, Combinations, and Ongoing Trials Sagar Lonial, MD, FACP \| Emory University, Atlanta, Georgia, USA – Chair Nina Shah, MD \| Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA Nikhil Munshi, MD \| Harvard Medical School, Boston, Massachusetts, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from GlaxoSmithKline and Oncopeptides, Inc.
INDEPENDENT SATELLITE SYMPOSIUM IX
	New Horizons in the Management of Myelodysplastic Syndromes: Exploring Advancements from Low- to High-Risk Disease Guillermo Garcia-Manero, MD \| University of Texas MD Anderson Cancer Center, Houston, Texas, USA - Chair David Steensma, MD \| Dana-Farber Cancer Institute, Boston, Massachusetts, USA Amy DeZern, MD \| Johns Hopkins University School of Medicine, Baltimore, Maryland, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants Agios Pharmaceuticals, Inc, Astex Pharmaceuticals, Inc, Bristol-Myers Squibb, and Takeda Oncology.
INDEPENDENT SATELLITE SYMPOSIUM X
	Illustrated Case Discussions: How Will You Leverage Recent Evidence in Relapsed/Refractory DLBCL Settings? Christopher R. Flowers, M.D., M.S. \| University of Texas MD Anderson Cancer Center, Houston, Texas, USA - Chair Kami Maddocks, MD \| The James Cancer Hospital at The Ohio State University, Columbus, Ohio, USA Loretta J. Nastoupil, MD \| University of Texas MD Anderson Cancer Center, Houston, Texas, USA Jason Westin, MD, MS, FACP \| University of Texas MD Anderson Cancer Center, Houston, Texas, USA This CME activity is provided by Physicians’ Education Resource, LLC. This activity is supported by educational grants from MorphoSys US Inc

scientific program

scientific program

SOHO 2020 Scientific Program

PROGRAM-AT-A-GLANCE

SOHO 2020 PROGRAM

About the Society of Hematologic Oncology